Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced it has secured a $53 million first close in Series C financing. The funds will be used to support development activities for the Katana Thrombectomy System and the NavIQ quantification software, completion of enrollment in the QUADRA-PE clinical trial and regulatory submissions.

Akura Medical是一家隶属于Shifamed的投资组合公司，专注于重塑静脉血栓栓塞症（VTE）护理的格局，该公司宣布已完成5300万美元的C轮融资首轮募集。这笔资金将用于支持Katana血栓切除系统和NavIQ量化软件的开发活动，完成QUADRA-PE临床试验的患者招募，以及监管提交。

The round was led by Qatar Investment Authority (QIA) with participation by current investors. Part of the funds will be used to set up a joint venture in Qatar..

本轮融资由卡塔尔投资局 (QIA) 领投，现有投资者参与。部分资金将用于在卡塔尔成立一家合资企业。